Acelot has dosed the first healthy volunteer in a Phase 1a clinical trial testing ACE-2223, its investigational oral treatment candidate designed to target aggregated TDP-43 in people with amyotrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results